EA200200596A1 - Окс (ади) азолилгидроксамовые кислоты, полезные в качестве ингибиторов проколлаген-с-протеиназы - Google Patents

Окс (ади) азолилгидроксамовые кислоты, полезные в качестве ингибиторов проколлаген-с-протеиназы

Info

Publication number
EA200200596A1
EA200200596A1 EA200200596A EA200200596A EA200200596A1 EA 200200596 A1 EA200200596 A1 EA 200200596A1 EA 200200596 A EA200200596 A EA 200200596A EA 200200596 A EA200200596 A EA 200200596A EA 200200596 A1 EA200200596 A1 EA 200200596A1
Authority
EA
Eurasian Patent Office
Prior art keywords
proteinase
inhibitors
progolagen
azolyl
adi
Prior art date
Application number
EA200200596A
Other languages
English (en)
Inventor
Саймон Бэйли
Стефан Биллотт
Эндрю Майкл Деррик
Пол Винсент Фиш
Ким Джеймс
Николас Мюррей Томсон
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200200596A1 publication Critical patent/EA200200596A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/48—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Соединения формулы (I) и их соли, сольваты, пролекарства и т.п., где заместители являются такими, как они определены в настоящем описании, представляют собой ингибиторы проколлаген-С-протеиназы (РСР) и могут быть использованы для лечения состояний, опосредованных РСР.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200596A 1999-12-23 2000-12-12 Окс (ади) азолилгидроксамовые кислоты, полезные в качестве ингибиторов проколлаген-с-протеиназы EA200200596A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9930570.8A GB9930570D0 (en) 1999-12-23 1999-12-23 Therapy
PCT/IB2000/001855 WO2001047901A1 (en) 1999-12-23 2000-12-12 Ox(adi)azolyl-hydroxamic acids useful as procollagen c-proteinase inhibitors

Publications (1)

Publication Number Publication Date
EA200200596A1 true EA200200596A1 (ru) 2002-12-26

Family

ID=10866986

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200596A EA200200596A1 (ru) 1999-12-23 2000-12-12 Окс (ади) азолилгидроксамовые кислоты, полезные в качестве ингибиторов проколлаген-с-протеиназы

Country Status (32)

Country Link
EP (1) EP1240152B1 (ru)
JP (1) JP2003519133A (ru)
KR (1) KR20020067570A (ru)
CN (1) CN1423638A (ru)
AP (1) AP2002002554A0 (ru)
AR (1) AR031085A1 (ru)
AT (1) ATE284393T1 (ru)
AU (1) AU1875601A (ru)
BG (1) BG106866A (ru)
BR (1) BR0016717A (ru)
CA (1) CA2395186C (ru)
CO (1) CO5261622A1 (ru)
DE (1) DE60016629T2 (ru)
EA (1) EA200200596A1 (ru)
EE (1) EE200200358A (ru)
ES (1) ES2231292T3 (ru)
GB (1) GB9930570D0 (ru)
GT (1) GT200000221A (ru)
HU (1) HUP0204585A3 (ru)
IL (1) IL149372A0 (ru)
IS (1) IS6363A (ru)
MA (1) MA26858A1 (ru)
MX (1) MXPA02006315A (ru)
NO (1) NO20023058L (ru)
OA (1) OA12125A (ru)
PA (1) PA8508301A1 (ru)
PE (1) PE20010951A1 (ru)
PL (1) PL357512A1 (ru)
SK (1) SK8102002A3 (ru)
TN (1) TNSN00250A1 (ru)
TR (1) TR200201642T2 (ru)
WO (1) WO2001047901A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6452041B1 (en) 2000-10-16 2002-09-17 Pfizer Inc. Olefination process to itaconate and succinate derivatives
GB0025310D0 (en) * 2000-10-16 2000-11-29 Pfizer Ltd Process
GB0031321D0 (en) * 2000-12-21 2001-02-07 Pfizer Ltd Treatment
US6716861B2 (en) 2000-12-21 2004-04-06 Pfizer, Inc. 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors
GB0108097D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6821972B2 (en) 2001-03-30 2004-11-23 Pfizer Inc. 3-heterocyclylpropanohydroxamic acid PCP inhibitors
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
GB0204159D0 (en) * 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE602005011784D1 (de) 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
WO2009097893A1 (en) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
EA031654B1 (ru) 2014-01-10 2019-02-28 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Гидроксиформамидные производные и их применение
CN108530378B (zh) * 2018-05-29 2021-09-14 济南大学 一类含有噁二唑结构的氮原子双取代异羟肟酸类化合物、用途及其制备方法
CN108721282B (zh) * 2018-07-13 2022-02-15 南京市儿童医院 Uk383367在制备用于减轻肾纤维化相关病症的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1812197A (en) * 1996-03-01 1997-09-16 Sankyo Company Limited Hydroxamic acid derivatives
CA2323208A1 (en) * 1998-03-10 1999-09-16 James M. Samanen Vitronectin receptor antagonists

Also Published As

Publication number Publication date
EE200200358A (et) 2003-10-15
AP2002002554A0 (en) 2002-06-30
MXPA02006315A (es) 2002-11-29
JP2003519133A (ja) 2003-06-17
BR0016717A (pt) 2002-09-03
NO20023058D0 (no) 2002-06-24
ES2231292T3 (es) 2005-05-16
CO5261622A1 (es) 2003-03-31
EP1240152B1 (en) 2004-12-08
PA8508301A1 (es) 2002-08-26
NO20023058L (no) 2002-08-23
MA26858A1 (fr) 2004-12-20
EP1240152A1 (en) 2002-09-18
DE60016629D1 (de) 2005-01-13
SK8102002A3 (en) 2003-09-11
CN1423638A (zh) 2003-06-11
TNSN00250A1 (fr) 2002-05-30
PE20010951A1 (es) 2001-09-24
PL357512A1 (en) 2004-07-26
AU1875601A (en) 2001-07-09
CA2395186A1 (en) 2001-07-05
HUP0204585A2 (hu) 2003-04-28
KR20020067570A (ko) 2002-08-22
WO2001047901A1 (en) 2001-07-05
TR200201642T2 (tr) 2002-11-21
OA12125A (en) 2006-05-05
ATE284393T1 (de) 2004-12-15
HUP0204585A3 (en) 2006-01-30
IL149372A0 (en) 2002-11-10
AR031085A1 (es) 2003-09-10
IS6363A (is) 2002-04-26
CA2395186C (en) 2006-03-28
BG106866A (bg) 2003-03-31
GT200000221A (es) 2002-06-14
GB9930570D0 (en) 2000-02-16
DE60016629T2 (de) 2005-12-08

Similar Documents

Publication Publication Date Title
EA200200596A1 (ru) Окс (ади) азолилгидроксамовые кислоты, полезные в качестве ингибиторов проколлаген-с-протеиназы
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA200300836A1 (ru) Производные фталазинон-пиперидина в качестве ингибиторов pde4
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
DK0931788T3 (da) Metalloproteasehæmmere
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
EA200200873A1 (ru) Новые пиперазиновые производные
DE69512797T2 (de) Prostaglandin-synthase hemmer
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
TR199902923T2 (xx) Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri.
EA200200253A1 (ru) Ингибиторы клеточной адгезии
EA199900953A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p38 КИНАЗЫ
EA199900643A1 (ru) Сульфамидные ингибиторы металлопротеаз
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
DE69511240T2 (de) Derivate des hydroxamsäure als metalloproteinaseinhibitoren
EA200200381A1 (ru) Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4
DK1242410T3 (da) Nye forbindelser
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
EA200100051A1 (ru) Ингибиторы fkbp
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла
CY1105373T1 (el) Ισοκινολινυλικα καρβοξαμιδια και η χρηση τους ως αντισπαστικα
DE60105028D1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung